<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="55">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05160428</url>
  </required_header>
  <id_info>
    <org_study_id>Post Covid Vaccination ARD</org_study_id>
    <nct_id>NCT05160428</nct_id>
  </id_info>
  <brief_title>Posy Covid-19 Vaccination Development or Flare of ARD</brief_title>
  <acronym>PoCov-ARD</acronym>
  <official_title>New or Flare of Musculoskeletal Rheumatic Diseases After Different COVID-19 Vaccines: Multicentre Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many patients develop autoimmune diseases after covid-19 vaccination, whether related to the&#xD;
      vaccination or not, is still under study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      II. Aim of the work:&#xD;
&#xD;
        -  Study new ARD and prevalence of different MSK manifestations after covid-19 vaccinations&#xD;
&#xD;
        -  Study prevalence of flare of ARD after covid-19 vaccinations&#xD;
&#xD;
        -  Comparison between different types and doses of covid-19 vaccinations in inducing ARD or&#xD;
           flares.&#xD;
&#xD;
      III. Method Study Design: Cross sectional study Study setting and duration: University as&#xD;
      well as general and insurance hospitals for a period of 3 months.&#xD;
&#xD;
      Sampling (Size and Method): All patients fulfilling the eligibility criteria will be enrolled&#xD;
      in the study.&#xD;
&#xD;
      IV. Participants&#xD;
&#xD;
      Target population:&#xD;
&#xD;
      any patient with pre-existing received any vaccination against covid-19 visiting rheumatology&#xD;
      outpatient clinic.&#xD;
&#xD;
      -any patient develops MSK manifestations after covid-19 vaccination.&#xD;
&#xD;
      Case Definition:&#xD;
&#xD;
      Eligibility Criteria:&#xD;
&#xD;
      Patients above 18 years old having MRD manifestations vaccinated against covid-19.&#xD;
&#xD;
      Inclusion Criteria:&#xD;
&#xD;
      Age above 18 years Vaccinated against covid-19 (one dose or fully vaccinated)&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
      Receiving other vaccine e.g influenza Less than 18 years old&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>-Prevalence of new ARD after covid-19 vaccinations</measure>
    <time_frame>3 moths</time_frame>
    <description>any ARD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>prevalence of flare of ARD after covid-19 vaccinations</measure>
    <time_frame>3 months</time_frame>
    <description>flare of any manifestations of the disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence of non-specific MSK symptoms after Covid-19 vaccine.</measure>
    <time_frame>3 months</time_frame>
    <description>any MSK symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the MSK to the 1st and 2nd Covid vaccine dose</measure>
    <time_frame>3 months</time_frame>
    <description>Correlation of the MSK to the 1st and 2nd Covid vaccine dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison between different type of covid-19 vaccine in inducing ARD or flare up.</measure>
    <time_frame>3 months</time_frame>
    <description>any type of flare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease activity status in the patients who developed the ARD symptoms before and after the vaccine.</measure>
    <time_frame>3 months</time_frame>
    <description>activity assessed by disease activity scores</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any correlation between the appearance of MSK symptoms and the patient's medications</measure>
    <time_frame>3 months</time_frame>
    <description>current medications</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>COVID-19</condition>
  <condition>Vaccination; Infection</condition>
  <condition>Rheumatic Diseases</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>COVID-19 vaccination</intervention_name>
    <description>different types of covid-19 vaccinations.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Eligibility Criteria:&#xD;
&#xD;
        Patients above 18 years old having MRD manifestations vaccinated against covid-19.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Age above 18 years Vaccinated against covid-19 (one dose or fully vaccinated)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Receiving other vaccine e.g influenza Less than 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 14, 2021</study_first_submitted>
  <study_first_submitted_qc>December 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2021</study_first_posted>
  <last_update_submitted>December 14, 2021</last_update_submitted>
  <last_update_submitted_qc>December 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Mervat Eissa</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Rheumatic Diseases</mesh_term>
    <mesh_term>Collagen Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

